Mumbai, India – February 5, 2025 – Innova Captab Limited (BSE: INNOVACAP, NSE: INNOVACAP) has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024.
Key Financial Highlights (₹ in million)
| Particulars | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 |
|---|---|---|---|---|---|
| Revenue from Operations | 3,164.62 | 3,182.03 | 3,024.85 | 9,289.35 | 8,186.71 |
| Total Income | 3,207.87 | 3,204.19 | 3,048.25 | 9,376.00 | 8,254.75 |
| EBITDA (Estimated from financials) | 508.86 | 519.49 | 469.37 | 1,467.35 | 1,133.58 |
| Profit Before Tax (PBT) | 455.88 | 468.09 | 352.01 | 1,317.05 | 899.84 |
| Net Profit (PAT) | 342.04 | 350.04 | 251.26 | 986.85 | 656.24 |
| EPS (₹ per share) | 5.97 | 6.12 | 4.39 | 17.25 | 11.47 |
- Revenue Growth: YoY revenue increased by 4.6% to ₹3,164.62 million.
- Profitability: Net profit rose 36.2% YoY, driven by higher operational efficiency.
- Earnings per Share: Increased to ₹5.97 in Q3 FY25 from ₹4.39 in Q3 FY24.
Standalone Financial Performance
Innova Captab’s standalone revenue stood at ₹2,485.25 million in Q3 FY25, compared to ₹2,364.60 million in Q3 FY24, reflecting a 5.1% YoY growth. Standalone profit after tax (PAT) grew to ₹244.02 million, up from ₹186.51 million in the corresponding quarter last year.Segmental & Strategic Updates
- Segment Focus: The company continues to operate in the "Drugs and Pharmaceutical Products" segment as per Ind-AS 108.
- Acquisition Impact: The inclusion of Sharon Bio-Medicine Limited (acquired on June 30, 2023) positively impacted revenue contributions.
- Regulatory Compliance: Amendments were adopted for policies related to insider trading, materiality, and related party transactions, aligning with SEBI’s latest guidelines.
Management Commentary
Vinay Lohariwala, Managing Director, stated: "We are pleased with our performance in Q3 FY25. The steady revenue growth and improved margins demonstrate the strength of our business model. We remain committed to expanding our footprint and enhancing operational efficiencies to drive sustainable growth."Outlook
- Growth Strategy: Continued expansion in domestic and international markets.
- Operational Efficiencies: Focus on optimizing cost structures to sustain margin improvements.
- R&D Investments: Strengthening pipeline for new product development.